Literature DB >> 33337329

Hidradenitis suppurativa and adalimumab in the COVID-19 era.

Angelo Valerio Marzano1, Chiara Moltrasio2, Giovanni Genovese1, Simona Muratori3, Paolo Dapavo4, Gabriella Fabbrocini5, Annalisa Patrizi6, Andrea Sechi6, Giuseppe Micali7, Michele Pellegrino8, Paolo Gisondi9, Valentina Dini10, Luca Bianchi11, Luca Fania12, Annamaria Offidani13, Francesca Prignano14, Laura Atzori15, Emanuele Miraglia16, Serafinella Patrizia Cannavò17, Vincenzo Bettoli18, Luca Stingeni19, Riccardo Balestri20, Marina Venturini21, Ketty Peris22.   

Abstract

Entities:  

Year:  2020        PMID: 33337329      PMCID: PMC7880651          DOI: 10.1684/ejd.2020.3927

Source DB:  PubMed          Journal:  Eur J Dermatol        ISSN: 1167-1122            Impact factor:   3.328


× No keyword cloud information.
  6 in total

1.  Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severity.

Authors:  C C Zouboulis; T Tzellos; A Kyrgidis; G B E Jemec; F G Bechara; E J Giamarellos-Bourboulis; J R Ingram; T Kanni; I Karagiannidis; A Martorell; Ł Matusiak; A Pinter; E P Prens; D Presser; S Schneider-Burrus; E von Stebut; J C Szepietowski; H H van der Zee; S M Wilden; R Sabat
Journal:  Br J Dermatol       Date:  2017-10-30       Impact factor: 9.302

2.  Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa.

Authors:  Alexa B Kimball; Martin M Okun; David A Williams; Alice B Gottlieb; Kim A Papp; Christos C Zouboulis; April W Armstrong; Francisco Kerdel; Michael H Gold; Seth B Forman; Neil J Korman; Evangelos J Giamarellos-Bourboulis; Jeffrey J Crowley; Charles Lynde; Ziad Reguiai; Errol-Prospero Prens; Eihab Alwawi; Nael M Mostafa; Brett Pinsky; Murali Sundaram; Yihua Gu; Dawn M Carlson; Gregor B E Jemec
Journal:  N Engl J Med       Date:  2016-08-04       Impact factor: 91.245

3.  Biologics for patients affected by hidradenitis suppurativa in the COVID-19 era: data from a referral center of Southern Italy.

Authors:  Claudio Marasca; Angelo Ruggiero; Matteo Megna; Maria Carmela Annunziata; Gabriella Fabbrocini
Journal:  J Dermatolog Treat       Date:  2020-05-25       Impact factor: 3.359

4.  Managing Cutaneous Immune-Mediated Diseases During the COVID-19 Pandemic.

Authors:  Tiago Torres; Luis Puig
Journal:  Am J Clin Dermatol       Date:  2020-06       Impact factor: 7.403

5.  Evidence for a 'window of opportunity' in hidradenitis suppurativa treated with adalimumab: a retrospective, real-life multicentre cohort study.

Authors:  A V Marzano; G Genovese; G Casazza; C Moltrasio; P Dapavo; G Micali; R Sirna; P Gisondi; A Patrizi; V Dini; D Bianchini; L Bianchi; L Fania; F Prignano; A Offidani; L Atzori; V Bettoli; S P Cannavò; M Venturini; M R Bongiorno; A Costanzo; G Fabbrocini; K Peris
Journal:  Br J Dermatol       Date:  2020-04-13       Impact factor: 9.302

6.  Adalimumab for treatment of hidradenitis suppurativa during the COVID-19 pandemic: Safety considerations.

Authors:  Alecia Blaszczak; John C L Trinidad; Alexander M Cartron
Journal:  J Am Acad Dermatol       Date:  2020-04-10       Impact factor: 11.527

  6 in total
  5 in total

1.  Impact of the COVID-19 pandemic on patients with hidradenitis suppurativa.

Authors:  Zeno Fiocco; Justin Gabriel Schlager; Benjamin Kendziora; Leilah Patzak; Sophie Kupf; Lars Einar French; Daniela Hartmann
Journal:  Int Wound J       Date:  2022-02-06       Impact factor: 3.099

2.  Low incidence of COVID-19 in hidradenitis suppurativa: How to interpret it?

Authors:  Mathilde Dewigne; Carmen Orte Cano; Mathieu Daoud; Véronique Del Marmol; Farida Benhadou
Journal:  Exp Dermatol       Date:  2021-11-03       Impact factor: 4.511

3.  How to Manage COVID-19 Vaccination in Immune-Mediated Inflammatory Diseases: An Expert Opinion by IMIDs Study Group.

Authors:  Francesca Ferretti; Rosanna Cannatelli; Maurizio Benucci; Stefania Carmagnola; Emilio Clementi; Piergiorgio Danelli; Dario Dilillo; Paolo Fiorina; Massimo Galli; Maurizio Gallieni; Giovanni Genovese; Valeria Giorgi; Alessandro Invernizzi; Giovanni Maconi; Jeanette A Maier; Angelo V Marzano; Paola S Morpurgo; Manuela Nebuloni; Dejan Radovanovic; Agostino Riva; Giuliano Rizzardini; Gianmarco Sabiu; Pierachille Santus; Giovanni Staurenghi; Gianvincenzo Zuccotti; Pier Carlo Sarzi-Puttini; Sandro Ardizzone
Journal:  Front Immunol       Date:  2021-04-15       Impact factor: 7.561

4.  Anti-COVID-19 measurements for hidradenitis suppurativa patients.

Authors:  Evangelos J Giamarellos-Bourboulis; Vincenzo Bettoli; Gregor B E Jemec; Veronique Del Marmol; Angelo V Marzano; Errol P Prens; Thrasyvoulos Tzellos; Christos C Zouboulis
Journal:  Exp Dermatol       Date:  2021-06       Impact factor: 3.960

Review 5.  Skin Manifestations in Psoriatic and HS Patients in Treatment with Biologicals during the COVID-19 Pandemic.

Authors:  Elia Rosi; Maria Thais Fastame; Antonella Di Cesare; Gianmarco Silvi; Nicola Pimpinelli; Francesca Prignano
Journal:  J Clin Med       Date:  2021-12-13       Impact factor: 4.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.